Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 randomized double-blind placebo-controlled study of dapansutrile for acute gout flare
MOH_2024-03-21_012925Phase 3Not yet recruiting
- Sponsor
- Olatec Therapeutics LLC
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute gout flare and gout comparing Dapansutrile tablets with Placebo tablets (2 arms). Primary endpoint: Reduction in target joint pain at 72 hours. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
dapansutrile
03
Conditions
acute gout flaregout
Beyond the preview
Go deeper on MOH_2024-03-21_012925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-21_012925.